(Q43041166)

12 November 2017

title

Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection (English)

1 reference

12 November 2017

1 reference

1 reference

Chuanlai Shen

1

1 reference

12 November 2017

Ting Hu

2

1 reference

12 November 2017

Ling Shen

3

1 reference

12 November 2017

Lei Gao

4

1 reference

12 November 2017

Wei Xie

5

1 reference

12 November 2017

Jianqiong Zhang

6

1 reference

12 November 2017

language of work or name

1 reference

1 November 2007

1 reference

Journal of Gastroenterology and Hepatology

12 November 2017

published in

1 reference

12 November 2017

volume

22

1 reference

12 November 2017

issue

11

1 reference

12 November 2017

page(s)

1898-1903

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Changes of HCV quasispecies during combination therapy with interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response,

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04566.X

10.1111/J.1440-1746.2006.04566.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference